Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.-论文-万方医学网

作者： Franck,Maunoury ^[1] ; Aurore,Clément ^[2] ; Chizoba,Nwankwo ^[3] ; Laurie,Levy-Bachelot ^[2] ; Armand,Abergel ^[4] ; Vincent,Di Martino ^[5] ; Eric,Thervet ^[6] ; Isabelle,Durand-Zaleski ^[7]

作者单位： Statesia, Le Mans, France. ^[1] MSD FRANCE, Paris, France. ^[2] Merck & Co., Inc., Kenilworth, New Jersey, United States of America. ^[3] Hepato-gastro enterology Service, CHU Estaing, Clermont-Ferrand, France. ^[4] Hepatology Department, Franche-Comté University and Besançon University hospital, Besançon, France. ^[5] HYPPARC Department, Nephrology Service, Paris Descartes University, Paris, France. ^[6] Georges Pompidou European Hospital (ET), Paris, France. ^[7] Ile-De-France URC ECO, Department of Public Health, Henri Mondor Hospital, Créteil, France. ^[8]

主题词酰胺类(Amides);抗病毒药(Antiviral Agents);苯呋喃类(Benzofurans);氨甲酸酯类(Carbamates);费用效益分析(Cost-Benefit Analysis);环丙烷类(Cyclopropanes);药物疗法, 联合(Drug Therapy, Combination);女(雌)性(Female);法国(France);基因型(Genotype);肝炎病毒属(Hepacivirus);丙型肝炎, 慢性(Hepatitis C, Chronic);人类(Humans);咪唑类(Imidazoles);肾功能衰竭, 慢性(Kidney Failure, Chronic);肝硬化(Liver Cirrhosis);男(雄)性(Male);中年人(Middle Aged);模型, 经济学(Models, Economic);质量校正寿命(Quality-Adjusted Life Years);喹恶啉类(Quinoxalines);RNA, 病毒(RNA, Viral);随机对照试验(主题)(Randomized Controlled Trials as Topic);肾透析(Renal Dialysis);磺胺类(Sulfonamides)

DOI 10.1371/journal.pone.0194329

PMID 29543897

发布时间 2024-03-14

检索历史清除

Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.

PloS one

相似文献

PloS one

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.

PloS one

相似文献

PloS one

相关期刊

检索历史清除